The University of Chicago Header Logo

Connection

David T. Rubin to Crohn Disease

Back to Details
This is a "connection" page, showing publications David T. Rubin has written about Crohn Disease.
David T. Rubin
Connection Strength
27.451
Crohn Disease
  1. Dose escalation of biologics in biologic-naive patients with Crohn's disease: Outcomes from the ODESSA-CD study. J Manag Care Spec Pharm. 2024 Nov; 30(11):1276-1287.
    View in: PubMed
    Score: 0.604
  2. Real-World Persistence of Successive Biologics in Patients With Inflammatory Bowel Disease: Findings From ROTARY. Inflamm Bowel Dis. 2024 Oct 03; 30(10):1776-1787.
    View in: PubMed
    Score: 0.601
  3. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY. BMC Gastroenterol. 2024 Sep 17; 24(1):314.
    View in: PubMed
    Score: 0.599
  4. Utility of the Endoscopic Healing Index in Identifying Active Inflammation in Patients with Crohn's Disease: Real World Data from a Tertiary Center. Dig Dis Sci. 2024 Aug; 69(8):2955-2960.
    View in: PubMed
    Score: 0.587
  5. Dual-Targeted Therapy with Upadacitinib and Ustekinumab in Medically Complex Crohn's Disease. Dig Dis Sci. 2024 Feb; 69(2):355-359.
    View in: PubMed
    Score: 0.569
  6. Risankizumab Effectiveness and Safety in Crohn's Disease: Real-world Data From a Large Tertiary Center. Clin Gastroenterol Hepatol. 2024 Jun; 22(6):1336-1338.e2.
    View in: PubMed
    Score: 0.568
  7. Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn's Disease: Prospective Real-World Experience. Clin Gastroenterol Hepatol. 2023 07; 21(7):1913-1923.e2.
    View in: PubMed
    Score: 0.539
  8. Treat-to-target and sequencing therapies in Crohn's disease. United European Gastroenterol J. 2022 12; 10(10):1121-1128.
    View in: PubMed
    Score: 0.530
  9. Diagnostic and Management Considerations for the IPAA With Crohn's Disease-Like Features. Dis Colon Rectum. 2022 12 01; 65(S1):S77-S84.
    View in: PubMed
    Score: 0.516
  10. Ileal Desmoid Tumor in Ileal Crohn's: Coincidence or Connection? Dig Dis Sci. 2023 03; 68(3):1071-1073.
    View in: PubMed
    Score: 0.513
  11. Upadacitinib Is Safe and Effective for Crohn's Disease: Real-World Data from a Tertiary Center. Dig Dis Sci. 2023 02; 68(2):385-388.
    View in: PubMed
    Score: 0.512
  12. Intestinal Cancer and Dysplasia in Crohn's Disease. Gastroenterol Clin North Am. 2022 06; 51(2):369-379.
    View in: PubMed
    Score: 0.507
  13. Histopathology of Colectomy Specimens Predicts Endoscopic Pouch Phenotype in Patients with Ulcerative Colitis. Dig Dis Sci. 2022 08; 67(8):4020-4031.
    View in: PubMed
    Score: 0.503
  14. International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey. Inflamm Bowel Dis. 2021 11 15; 27(12):1942-1953.
    View in: PubMed
    Score: 0.492
  15. Inclusion of Under-represented Racial and Ethnic Minorities in Randomized Clinical Trials for Inflammatory Bowel Disease. Gastroenterology. 2022 01; 162(1):17-21.
    View in: PubMed
    Score: 0.487
  16. The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies. Inflamm Bowel Dis. 2021 07 27; 27(8):1201-1209.
    View in: PubMed
    Score: 0.482
  17. New targets in inflammatory bowel disease therapy: 2021. Curr Opin Gastroenterol. 2021 07 01; 37(4):357-363.
    View in: PubMed
    Score: 0.480
  18. Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease. United European Gastroenterol J. 2021 06; 9(5):552-560.
    View in: PubMed
    Score: 0.474
  19. Temporal Improvement of a COVID-19-Positive Crohn's Disease Patient Treated With Bismuth Subsalicylate. Am J Gastroenterol. 2020 08; 115(8):1298.
    View in: PubMed
    Score: 0.450
  20. Poor Sleep Quality in Crohn's Disease Is Associated With Disease Activity and Risk for Hospitalization or Surgery. Inflamm Bowel Dis. 2020 07 17; 26(8):1251-1259.
    View in: PubMed
    Score: 0.449
  21. Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology. 2020 Jul; 159(1):6-13.e6.
    View in: PubMed
    Score: 0.440
  22. Inpatient Management of Inflammatory Bowel Disease-Related Complications. Clin Gastroenterol Hepatol. 2020 05; 18(6):1346-1355.
    View in: PubMed
    Score: 0.433
  23. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. Clin Gastroenterol Hepatol. 2020 10; 18(11):2518-2525.e1.
    View in: PubMed
    Score: 0.430
  24. Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. J Crohns Colitis. 2019 Sep 19; 13(9):1158-1162.
    View in: PubMed
    Score: 0.424
  25. Methotrexate for the Treatment of Pediatric Crohn's Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2018 09 15; 24(10):2135-2141.
    View in: PubMed
    Score: 0.395
  26. Higher Thioguanine Nucleotide Metabolite Levels are Associated With Better Long-term Outcomes in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol. 2018 07; 52(6):537-544.
    View in: PubMed
    Score: 0.390
  27. Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety. Inflamm Bowel Dis. 2018 03 19; 24(4):849-860.
    View in: PubMed
    Score: 0.382
  28. Assessment of peri-polyp biopsy specimens of flat mucosa in patients with inflammatory bowel disease. Gastrointest Endosc. 2018 May; 87(5):1304-1309.
    View in: PubMed
    Score: 0.377
  29. Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLoS One. 2017; 12(4):e0175099.
    View in: PubMed
    Score: 0.359
  30. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis. J Manag Care Spec Pharm. 2017 Aug; 23(8):859-867.
    View in: PubMed
    Score: 0.356
  31. The Crohn's and Colitis Foundation of America Survey of Inflammatory Bowel Disease Patient Health Care Access. Inflamm Bowel Dis. 2017 02; 23(2):224-232.
    View in: PubMed
    Score: 0.353
  32. Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis. Curr Med Res Opin. 2017 03; 33(3):529-536.
    View in: PubMed
    Score: 0.352
  33. Zinc Deficiency is Associated with Poor Clinical Outcomes in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017 01; 23(1):152-157.
    View in: PubMed
    Score: 0.351
  34. Safety and Efficacy of Live Measles Vaccine Administered to a Crohn's Disease Patient Receiving Vedolizumab. Am J Gastroenterol. 2016 04; 111(4):577.
    View in: PubMed
    Score: 0.333
  35. Vedolizumab in the treatment of Crohn's disease. Expert Rev Gastroenterol Hepatol. 2016; 10(3):283-90.
    View in: PubMed
    Score: 0.329
  36. Penetrating Disease, Narcotic Use, and Loop Ostomy Are Associated with Ostomy and IBD-related Complications After Ostomy Surgery in Crohn's Disease Patients. J Gastrointest Surg. 2015 Oct; 19(10):1852-61.
    View in: PubMed
    Score: 0.319
  37. Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. Aliment Pharmacol Ther. 2014 May; 39(10):1143-55.
    View in: PubMed
    Score: 0.290
  38. Describing the clinical phenotypes of Crohn's disease: lessons from the past: commentary on: the broadening conception of regional ileitis. Dig Dis Sci. 2014 Jan; 59(1):6-8.
    View in: PubMed
    Score: 0.285
  39. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease. Inflamm Bowel Dis. 2013 Nov; 19(12):2577-83.
    View in: PubMed
    Score: 0.282
  40. Initial experience of a through-the-scope balloon device for ileal intubation in Crohn's disease. Gastrointest Endosc. 2013 Oct; 78(4):669-70.
    View in: PubMed
    Score: 0.280
  41. Chronic pouchitis versus recurrent Crohn's disease: a diagnostic challenge. Dig Dis Sci. 2013 Oct; 58(10):2748-50.
    View in: PubMed
    Score: 0.277
  42. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis. 2013 Mar; 19(3):621-6.
    View in: PubMed
    Score: 0.269
  43. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012 Dec; 18(12):2225-31.
    View in: PubMed
    Score: 0.251
  44. Assessment of variables associated with smoking cessation in Crohn's disease. Dig Dis Sci. 2012 Apr; 57(4):1026-32.
    View in: PubMed
    Score: 0.250
  45. Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflamm Bowel Dis. 2012 May; 18(5):818-25.
    View in: PubMed
    Score: 0.243
  46. A practical, evidence-based guide to the use of adalimumab in Crohn's disease. Curr Med Res Opin. 2011 Sep; 27(9):1803-13.
    View in: PubMed
    Score: 0.241
  47. Predictors of adalimumab dose escalation in patients with Crohn's disease at a tertiary referral center. Inflamm Bowel Dis. 2012 Jan; 18(1):10-6.
    View in: PubMed
    Score: 0.236
  48. Active Crohn's disease in the small bowel: evaluation by diffusion weighted imaging and quantitative dynamic contrast enhanced MR imaging. J Magn Reson Imaging. 2011 Mar; 33(3):615-24.
    View in: PubMed
    Score: 0.234
  49. Colorectal cancer and dysplasia in inflammatory bowel disease. World J Gastroenterol. 2008 May 07; 14(17):2662-9.
    View in: PubMed
    Score: 0.193
  50. p53 mutations are associated with dysplasia and progression of dysplasia in patients with Crohn's disease. Dig Dis Sci. 2008 Feb; 53(2):474-80.
    View in: PubMed
    Score: 0.183
  51. Superior mesenteric vein thrombosis after colectomy in a patient with Crohn's disease. Nat Clin Pract Gastroenterol Hepatol. 2005 Jun; 2(6):281-5; quiz 1 p following 285.
    View in: PubMed
    Score: 0.157
  52. To test or "NOD-2" test: what are the questions? The balanced viewpoint. Inflamm Bowel Dis. 2005 May; 11(5):510-2.
    View in: PubMed
    Score: 0.156
  53. Overview to Challenges in IBD 2024-2029. Inflamm Bowel Dis. 2024 May 23; 30(Supplement_2):S1-S4.
    View in: PubMed
    Score: 0.147
  54. Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Crohn's Disease in US and Europe: Results from the Cross-Sectional CONFIDE Study. Dig Dis Sci. 2024 Jul; 69(7):2333-2344.
    View in: PubMed
    Score: 0.146
  55. Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn's Disease Regardless of Prior Biologic Exposure. Clin Gastroenterol Hepatol. 2024 Oct; 22(10):2096-2106.
    View in: PubMed
    Score: 0.145
  56. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial. Lancet Gastroenterol Hepatol. 2024 Feb; 9(2):133-146.
    View in: PubMed
    Score: 0.142
  57. Crohn's Disease Features in Anastomotic Biopsies from Patients With and Without Crohn's Disease: Diagnostic and Prognostic Value. Mod Pathol. 2023 Nov; 36(11):100325.
    View in: PubMed
    Score: 0.139
  58. Treatment of Chronic Inflammatory Pouch Conditions With Tofacitinib: A Case Series From 2 Tertiary IBD Centers in the United States. Inflamm Bowel Dis. 2023 09 01; 29(9):1504-1507.
    View in: PubMed
    Score: 0.139
  59. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol Hepatol. 2023 09; 8(9):853-859.
    View in: PubMed
    Score: 0.138
  60. Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions. J Crohns Colitis. 2023 Jul 05; 17(7):1066-1078.
    View in: PubMed
    Score: 0.138
  61. Transient Suppression of Bacterial Populations Associated with Gut Health is Critical in Success of Exclusive Enteral Nutrition for Children with Crohn's Disease. J Crohns Colitis. 2023 Jul 05; 17(7):1103-1113.
    View in: PubMed
    Score: 0.138
  62. Development of the global inflammatory bowel disease visualization of epidemiology studies in the 21st century (GIVES-21). BMC Med Res Methodol. 2023 05 25; 23(1):129.
    View in: PubMed
    Score: 0.137
  63. Ultrasonographic Transmural Healing in Crohn's Disease. Am J Gastroenterol. 2023 06 01; 118(6):961-969.
    View in: PubMed
    Score: 0.135
  64. Long-Term Outcomes of the Excluded Rectum in Crohn's Disease: A Multicenter International Study. Inflamm Bowel Dis. 2023 03 01; 29(3):417-422.
    View in: PubMed
    Score: 0.135
  65. Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial. Aliment Pharmacol Ther. 2023 01; 57(2):205-214.
    View in: PubMed
    Score: 0.132
  66. Recommendations for Standardizing Clinical Trial Design and Endoscopic Assessment in Postoperative Crohn's Disease. Inflamm Bowel Dis. 2022 09 01; 28(9):1321-1331.
    View in: PubMed
    Score: 0.130
  67. Global Hospitalization Trends for Crohn's Disease and Ulcerative Colitis in the 21st Century: A Systematic Review With Temporal Analyses. Clin Gastroenterol Hepatol. 2023 08; 21(9):2211-2221.
    View in: PubMed
    Score: 0.129
  68. CORE-IBD: A Multidisciplinary International Consensus Initiative to Develop a Core Outcome Set for Randomized Controlled Trials in Inflammatory Bowel Disease. Gastroenterology. 2022 10; 163(4):950-964.
    View in: PubMed
    Score: 0.129
  69. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022 05 28; 399(10340):2015-2030.
    View in: PubMed
    Score: 0.128
  70. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022 05 28; 399(10340):2031-2046.
    View in: PubMed
    Score: 0.128
  71. Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey. Lancet Gastroenterol Hepatol. 2022 05; 7(5):390-391.
    View in: PubMed
    Score: 0.127
  72. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. Lancet Gastroenterol Hepatol. 2022 07; 7(7):666-678.
    View in: PubMed
    Score: 0.127
  73. IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. Clin Gastroenterol Hepatol. 2022 11; 20(11):2619-2627.e1.
    View in: PubMed
    Score: 0.125
  74. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study. Gastroenterology. 2022 05; 162(6):1650-1664.e8.
    View in: PubMed
    Score: 0.125
  75. What Does Disease Progression Look Like in Ulcerative Colitis, and How Might It Be Prevented? Gastroenterology. 2022 04; 162(5):1396-1408.
    View in: PubMed
    Score: 0.125
  76. Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium. Lancet Gastroenterol Hepatol. 2022 01; 7(1):69-95.
    View in: PubMed
    Score: 0.123
  77. Fecal Calprotectin Is Highly Effective to Detect Endoscopic Ulcerations in Crohn's Disease Regardless of Disease Location. Inflamm Bowel Dis. 2021 06 15; 27(7):1008-1016.
    View in: PubMed
    Score: 0.120
  78. Older Adult Patients Use More Aminosalicylate Monotherapy Compared With Younger Patients With Inflammatory Bowel Disease: TARGET-IBD. J Clin Gastroenterol. 2022 07 01; 56(6):529-535.
    View in: PubMed
    Score: 0.119
  79. Evolving role of endoscopy in inflammatory bowel disease: Going beyond diagnosis. World J Gastroenterol. 2021 May 28; 27(20):2521-2530.
    View in: PubMed
    Score: 0.119
  80. Predictability of simple endoscopic score for Crohn's disease for postoperative outcomes in Crohn's disease. J Gastroenterol Hepatol. 2021 Oct; 36(10):2785-2793.
    View in: PubMed
    Score: 0.119
  81. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021 04; 160(5):1570-1583.
    View in: PubMed
    Score: 0.117
  82. The Correlation between Vitamin D Levels and the Risk of Postoperative Recurrence in Crohn's Disease. Digestion. 2021; 102(5):767-775.
    View in: PubMed
    Score: 0.117
  83. Daily Aspirin Use Does Not Impact Clinical Outcomes in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021 01 19; 27(2):236-241.
    View in: PubMed
    Score: 0.116
  84. Real-World Effectiveness and Safety of Tofacitinib in Crohn's Disease and IBD-U: A Multicenter Study From the TROPIC Consortium. Clin Gastroenterol Hepatol. 2021 10; 19(10):2207-2209.e3.
    View in: PubMed
    Score: 0.114
  85. An International Multicenter Comparison of IBD-Related Disability and Validation of the IBDDI. Clin Gastroenterol Hepatol. 2021 12; 19(12):2524-2531.
    View in: PubMed
    Score: 0.113
  86. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2021 01; 19(1):104-110.
    View in: PubMed
    Score: 0.109
  87. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis. 2020 01 06; 26(2):304-313.
    View in: PubMed
    Score: 0.108
  88. Capsule Retention in Crohn's Disease: A Meta-analysis. Inflamm Bowel Dis. 2020 01 01; 26(1):33-42.
    View in: PubMed
    Score: 0.108
  89. The Cost of Inflammatory Bowel Disease: An Initiative From the Crohn's & Colitis Foundation. Inflamm Bowel Dis. 2020 01 01; 26(1):1-10.
    View in: PubMed
    Score: 0.108
  90. Renin-angiotensin system promotes colonic inflammation by inducing TH17 activation via JAK2/STAT pathway. Am J Physiol Gastrointest Liver Physiol. 2019 06 01; 316(6):G774-G784.
    View in: PubMed
    Score: 0.103
  91. Differential risk of disease progression between isolated anastomotic ulcers and mild ileal recurrence after ileocolonic resection in patients with Crohn's disease. Gastrointest Endosc. 2019 08; 90(2):269-275.
    View in: PubMed
    Score: 0.102
  92. Incidence of Arthritis/Arthralgia in Inflammatory Bowel Disease with Long-term Vedolizumab Treatment: Post Hoc Analyses of the GEMINI Trials. J Crohns Colitis. 2019 Jan 01; 13(1):50-57.
    View in: PubMed
    Score: 0.101
  93. A comparison of the risk of postoperative recurrence between African-American and Caucasian patients with Crohn's disease. Aliment Pharmacol Ther. 2018 11; 48(9):933-940.
    View in: PubMed
    Score: 0.098
  94. Utility of video capsule endoscopy for longitudinal monitoring of Crohn's disease activity in the small bowel: a prospective study. Gastrointest Endosc. 2018 12; 88(6):947-955.e2.
    View in: PubMed
    Score: 0.098
  95. Efficacy of Vedolizumab in Fistulising Crohn's Disease: Exploratory Analyses of Data from GEMINI 2. J Crohns Colitis. 2018 Apr 27; 12(5):621-626.
    View in: PubMed
    Score: 0.096
  96. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology. 2018 07; 155(1):76-87.
    View in: PubMed
    Score: 0.096
  97. The Use of Vedolizumab in Preventing Postoperative Recurrence of Crohn's Disease. Inflamm Bowel Dis. 2018 02 15; 24(3):502-509.
    View in: PubMed
    Score: 0.095
  98. Long-term Efficacy of Vedolizumab for Crohn's Disease. J Crohns Colitis. 2017 Apr 01; 11(4):412-424.
    View in: PubMed
    Score: 0.089
  99. The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions. Dig Dis Sci. 2017 04; 62(4):833-842.
    View in: PubMed
    Score: 0.089
  100. Many Inflammatory Bowel Disease Patients Are Not Immune to Measles or Pertussis. Dig Dis Sci. 2016 10; 61(10):2972-2976.
    View in: PubMed
    Score: 0.086
  101. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
    View in: PubMed
    Score: 0.085
  102. Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel. Inflamm Bowel Dis. 2016 06; 22(6):1418-24.
    View in: PubMed
    Score: 0.084
  103. Age of Diagnosis is Associated with Disease Presentation and Therapeutic Complications in Patients with Crohn's Disease. Inflamm Bowel Dis. 2016 May; 22(5):1027-31.
    View in: PubMed
    Score: 0.084
  104. Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia. Inflamm Bowel Dis. 2016 Mar; 22(3):631-7.
    View in: PubMed
    Score: 0.083
  105. Understanding Endoscopic Disease Activity in IBD: How to Incorporate It into Practice. Curr Gastroenterol Rep. 2016 Jan; 18(1):5.
    View in: PubMed
    Score: 0.082
  106. Health Insurance Paid Costs and Drivers of Costs for Patients With Crohn's Disease in the United States. Am J Gastroenterol. 2016 Jan; 111(1):15-23.
    View in: PubMed
    Score: 0.079
  107. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):1919-25.
    View in: PubMed
    Score: 0.078
  108. Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
    View in: PubMed
    Score: 0.075
  109. Clinical presentation and disease course of inflammatory bowel disease differs by race in a large tertiary care hospital. Dig Dis Sci. 2014 Sep; 59(9):2228-35.
    View in: PubMed
    Score: 0.073
  110. Assessment of the relationship between quality of sleep and disease activity in inflammatory bowel disease patients. Inflamm Bowel Dis. 2013 Oct; 19(11):2440-3.
    View in: PubMed
    Score: 0.070
  111. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis. 2013 May; 19(6):1112-22.
    View in: PubMed
    Score: 0.068
  112. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 2013 Feb; 19(2):363-9.
    View in: PubMed
    Score: 0.067
  113. Genetic testing for inflammatory bowel disease: focus group analysis of patients and family members. Genet Test Mol Biomarkers. 2009 Aug; 13(4):495-503.
    View in: PubMed
    Score: 0.052
  114. Quantitative analysis of dynamic contrast enhanced MRI for assessment of bowel inflammation in Crohn's disease pilot study. Acad Radiol. 2009 Oct; 16(10):1223-30.
    View in: PubMed
    Score: 0.052
  115. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. Am J Gastroenterol. 2008 Dec; 103(12):3132-41.
    View in: PubMed
    Score: 0.050
  116. Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation. Lab Invest. 2008 Oct; 88(10):1110-20.
    View in: PubMed
    Score: 0.049
  117. The complexity and challenges of genetic counseling and testing for inflammatory bowel disease. J Genet Couns. 2006 Dec; 15(6):465-76.
    View in: PubMed
    Score: 0.044
  118. Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation. Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):113-6; quiz 1 p following 116.
    View in: PubMed
    Score: 0.038
  119. Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD. J Crohns Colitis. 2024 Apr 23; 18(4):548-559.
    View in: PubMed
    Score: 0.036
  120. Long-term safety of vedolizumab for inflammatory bowel disease. Aliment Pharmacol Ther. 2020 10; 52(8):1353-1365.
    View in: PubMed
    Score: 0.028
  121. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020 06; 51(12):1365-1372.
    View in: PubMed
    Score: 0.028
  122. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
    View in: PubMed
    Score: 0.026
  123. Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. J Crohns Colitis. 2017 Oct 01; 11(10):1180-1199.
    View in: PubMed
    Score: 0.023
  124. Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases. J Crohns Colitis. 2016 Dec; 10(12):1385-1394.
    View in: PubMed
    Score: 0.021
  125. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut. 2011 Jul; 60(7):937-43.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.